Imaging of 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis

Cristina Zavaleta, Beth Goins, Ande Bao, Linda Mcmanus, C. Alex Mcmahan, William Phillips

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

This study determined the biodistribution of rhenium-186 (186Re) encapsulated in biotin-liposomes containing patent blue dye, injected intraperitoneally (IP) with avidin in an OVCAR-3 ovarian cancer xenograft model and evaluated tumor response of this therapy with fluorine-18-fluorodeoxyglucose (18F-FDG) microPET imaging. Treated rats (n = 8) received an IP injection of 186Re- blue-biotin-liposomes (1000 MBq/kg) 30 min before an IP injection of avidin (5 mg), whereas control rats (n = 4) received a sham IP injection of saline. Scintigraphic images showed that 186Re-blue-biotin liposomes/avidin were retained in the peritoneal cavity with 18% of the original activity remaining after 5 days. From 1 to 4 weeks post-treatment, peritoneal 18F-FDG standard uptake values decreased 30% in treatment group, yet increased 44% in control group. Total number of cells in ascites was significantly higher in control versus treatment group. Omental fat in control rats had numerous tumor cells compared with treated rats. Results show the potential for 186Re- blue-biotin-liposome/avidin system in treating advanced ovarian cancer involving peritoneal carcinomatosis.

Original languageEnglish (US)
Pages (from-to)626-637
Number of pages12
JournalJournal of Drug Targeting
Volume16
Issue number7-8
DOIs
StatePublished - Aug 15 2008

Keywords

  • Avidin
  • Biotin-liposomes
  • Intraperitoneal delivery
  • Positron emission tomography
  • Radionuclide therapy
  • Single photon emission computed tomography

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Imaging of <sup>186</sup>Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis'. Together they form a unique fingerprint.

Cite this